Wednesday, October 14, 2026
Via News Knowledge File

Netflix Inc.

organization80% conf.·synced Oct 14, 2026

Streaming entertainment service company

60
sourced metrics
1006
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd
-22.6%
Oct 13, 2026reference only
Stock Price
70.46USD
Oct 13, 2026reference only
Price 52 Week High
1241.35USD
Oct 13, 2026reference only
Market Cap
293391189571USD
Oct 13, 2026reference only
Price 52 Week Low
67.06USD
Oct 13, 2026reference only
Rd Expense
1007675000.0USD
Jun 30, 2026reference only
Cash
9099232000.0USD
Jun 30, 2026reference only
Total Assets
58450441000.0USD
Jun 30, 2026reference only
Total Liabilities
28298389000.0USD
Jun 30, 2026reference only
Stockholders Equity
30152052000.0USD
Jun 30, 2026reference only
Operating Cash Flow
1743812000.0USD
Jun 30, 2026reference only
Net Income
3401414000.0USD
Jun 30, 2026reference only
Cost Of Revenue
6036965000.0USD
Jun 30, 2026reference only
Shares Outstanding
4163939676.0shares
Jun 30, 2026reference only
Revenue
12559938000.0USD
Jun 30, 2026reference only
Eps
0.8USD_per_share
Jun 30, 2026reference only
Capex
218644000.0USD
Jun 30, 2026reference only
Operating Income
4192610000.0USD
Jun 30, 2026reference only

Stated objectives

Achieve 31.5% operating margin

source
target: 31.5% by 2026-01-01 00:00:00stated

Achieve $3 billion in ad revenue (doubling from 2025)

source
target: 3 billion USD by 2026-01-01 00:00:00stated

Achieve 14% year-over-year revenue growth

source
target: 14% by 2026-01-01 00:00:00stated

Maintain content cash spend at $17 billion (growing slower than revenue)

source
target: 17 billion USD by 2026-01-01 00:00:00stated

Generate approximately $6 billion in free cash flow

source
target: 6 billion USD by 2026-01-01 00:00:00stated

Roll out proprietary ad tech stack to all ad markets

source
target: 12 countries by 2025-01-01 00:00:00stated

Add 2+ live operation centers in UK and Asia

source
target: 2+ by 2026-01-01 00:00:00stated

Operating margin guidance for Q1

source
target: 32.1% by 2026-01-01 00:00:00stated

Q1 2026 operating margin guidance

source
target: 32.1% by 2026-01-01 00:00:00stated

Q1 2026 operating margin

source
target: 32.1% stated

Relationship graph · 1006 connections

Covered by
413
Competes with
145
Developed by
47
Employs
46
rates
44
acquired by
40
licensed from
21
Invested in
21

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com